Advances in the treatment of luminal breast cancer

Current Opinion in Obstetrics and Gynecology

Volumn 25, Issue 1, 2013, Pages 49-54

  Howell, Sacha J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

everolimus; fulvestrant; genomic profiling; luminal; resistance

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; LAPATINIB; LETROZOLE; RAPAMYCIN; TAMOXIFEN; TEMSIROLIMUS;

ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANEMIA; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GENE DOSAGE; GENE EXPRESSION; GENE SEQUENCE; HORMONAL THERAPY; HUMAN; HYPERGLYCEMIA; IMMUNOFLUORESCENCE; LOADING DRUG DOSE; MONOTHERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK REDUCTION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

BREAST NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84873081621     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32835c0410     Document Type: Review

References (40)

1. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method for treatment with illustrative cases. Lancet 1896; 2:162-165.
2. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17:1474-1481.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771-784.
4. Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Systematic Rev 2009; 4:CD003370.
5. Mauri D, Pavlidis N, Polyzos NP, et al. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. JNCI 2006; 98:1285-1291.
6. Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20:1771-1785.
7. Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012; 21:242-252.
8. Iwamoto T, Booser D, Valero V, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1 to 10 ER-positive by immunohistochemistry. J Clin Oncol 2012; 30:729-734.
9. Collins LC, Botero ML, Scnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results of 825 cases. Am J Clin Pathol 2005; 123:16-20.
10. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5993 breast cancers. Am J Clin Pathol 2005; 123:21-27.
11. Kim C, Tang G, Pogue-Geile KL, et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol 2011; 29:4160-4167.
12. Bastien RR, Rodríguez-Lescure A, Ebbert MT, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 2012; 5:44.
13. Chia SK, Bramwell VH, Tu D, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 2012; 18:4465-4472.
14. Paik S, Tang G, Shak S, et al.Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:1-12.
15. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with nodepositive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11:55-65.
16. Mamounas EP, Tang G, Paik S, et al. Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: results from NSAB B-28. J Clin Oncol 2012; 30 (suppl 27):abstr 1.
17. Prat A, Parker JS, Fan C, et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 2012; 23:2866-2873.
18. Kelly CM, Bernard PS, Krishnamurthy S, et al. Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX1) and the PAM50 breast cancer intrinsic ClassifierTM in early-stage estrogen receptorpositive breast cancer. Oncologist 2012; 17:492-498.
19. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011; 29:4273-4278.
20. Christiansen J, Bartlett JMS, Gustavson M, et al. Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches. J Clin Oncol 2012; 30 (suppl):abstr 517.
21. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103:1656-1664.
22. Curtis C, Shah SP, Chin S, et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012; 486:346-352.
23. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486:353-360.
24. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486:400-404.
25. Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500mg versus anastrozole 1mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat 2012; 136:503-511.
26. Macedo LF, Sabnis GJ, Goloubeva OG, et al. Combination of anastrazole with fulvestrant in the intratumoural aromatase xenograft model. Cancer Res 2008; 68:3516-3522.
27. Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367:435-444.
28. Bergh J, Jonsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor positive postmenopausal breast cancer. J Clin Oncol 2012; 30:1919-1925.
29. Johnston S, Kilburn LS, Ellis P, et al. Fulvestrant alone or with concomitant anastrozole vs exemestane following progression on nonsteroidal aromatase inhibitor-first results of the SoFEA Trial. Eur J Cancer 2012; 48:S2 (LBA2).
30. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM Phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28:4594-4600.
31. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008; 10:1664-1670.
32. Schmid P, Turner P, Howlett M. Adjusted indirect comparison analysis demonstrates significant benefit in progression-free survival for fulvestrant 500mg compared to anastrazole in advanced breast cancer. Ann Oncol 2012; 23(Suppl 9):7-30.
33. Cardoso F, Bischoff J, Brain E, et al. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treat Rev 2012. [Epub ahead of print]
34. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptorpositive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30:2718-2724.
35. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27:5538-5546.
36. Cristofanilli M, Valero V, Mangalik A, et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010; 16:1904-1914.
37. Osborne CK, Neven P, Dirix LY, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011; 17:1147-1159.
38. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520-529.
39. Bhattacharyya G, Biswas J, Singh J, et al. Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast cancer. Eur J Cancer 2011; 47 Suppl 3:S4-388.
40. Chow LWS, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausalwomen with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl 1):6091.